Author:
Morgenstern Peter F.,Marongiu Roberta,Musatov Sergei A.,Kaplitt Michael G.
Reference52 articles.
1. Dreyer, J. L. Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions Methods Mol Biol 614, 3–35.
2. Jarraya, B., Boulet, S., Ralph, G. S., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., Herard, A. S., Day, D. M., Brouillet, E., Kingsman, S. M., Hantraye, P., Mitrophanous, K. A., Mazarakis, N. D., and Palfi, S. (2009) Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia Sci Transl Med 1, 2ra4.
3. Manfredsson, F. P., and Mandel, R. J. (2010) Development of gene therapy for neurological disorders Discov Med 9, 204–211.
4. Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., and During, M. J. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: an open label, phase I trial Lancet 369, 2097–2105.
5. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O’Malley, K. L., and During, M. J. (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain Nat Genet 8, 148–154.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献